Dr. Robert Kreitman explains how CD22-targeted CAR T could help heavily pretreated patients.
|Articles|March 9, 2009
- Special Issue 2006
- Volume 5
- Issue 3
Web Exclusive: Books by Wendy Harpham
Author(s)Kathy LaTour
Reviews of books written by Wendy Harpham.
Advertisement
Diganosed with non-Hodgkin lymphoma in 1990, Wendy Harpham, MD, is a "physican-survivor" and author of six books.
Read reviews of Harpham's books from the
Articles in this issue
over 17 years ago
Complementing Mainstream Treatmentover 17 years ago
Causes and Treatments for Long-Term and Late Effectsover 17 years ago
Timelineover 17 years ago
In Her Own Wordsabout 20 years ago
Message from the LAF's President and CEOabout 20 years ago
Letters to Lanceabout 20 years ago
An Update from Friendsabout 20 years ago
A Survivor's Mapabout 20 years ago
The Man Who Redefined 'Survivor'about 20 years ago
What a Survivorship Prescription Looks LikeAdvertisement
Related to this article
Testicular cancer survivor Brian Sluga shares how faith, journaling and new goals, like training for marathons, helped him live a better life after cancer.
Five phase 3 trials presented at ESMO 2026 showed new options in small cell lung, bladder, prostate, KRAS G12C lung and stomach cancers. Here is what each found and what it means for patients.
An expert discusses infection risks after treatment, what follow-up care looks like and why patients with a rare cancer should ask questions, seek expert opinions and find community.
Median survival, hazard ratio, progression-free survival: a plain-language guide to the terms in cancer trial news, so you can tell what a result means for you and what to ask your care team.
Dr. Robert J. Kreitman explains how an experimental CAR T-cell therapy may help patients with relapsed hairy cell leukemia achieve lasting remissions.
Dr. Jacqueline Barrientos discussed how collaboration, individualized treatment and patient advocacy helped a 72-year-old man achieve leukemia remission and receive a kidney transplant.
Adding Imdelltra to Imfinzi maintenance helped people with extensive-stage small cell lung cancer live a median of 21.1 months vs. 12.7 months with Imfinzi alone in the phase 3 DeLLphi-305 trial.
Advertisement
Advertisement
Trending on CURE
1
Top 5 Takeaways From ESMO 2026 That Patients Should Know
2
What New KRAS Drug Data From ESMO 2026 Mean for Patients
3
What Liquid Biopsy and ESR1 Mutations Mean in Breast Cancer
4
Psychiatrist Answers Questions About Family and Relationships During Cancer
5